期刊
LEUKEMIA
卷 28, 期 8, 页码 1606-1616出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2014.64
关键词
-
资金
- AIRC [IG10519, 5xMille10007, 14355]
- Centro Interdipartimentale per la Ricerca sul Cancro 'G. Prodi', BolognAIL, RFO
- FIRB [RBFR12D1CB]
- Fondazione Cassa di Risparmio in Bologna
- Fondazione della Banca del Monte e Ravenna
- Progetto Strategic di Ateneo
- MIUR (PRIN)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease of controversial origin recently recognized as a neoplasm deriving from plasmacytoid dendritic cells (pDCs). Nevertheless, it remains an orphan tumor with obscure biology and dismal prognosis. To better understand the pathobiology of BPDCN and discover new targets for effective therapies, the gene expression profile (GEP) of 25 BPDCN samples was analyzed and compared with that of pDCs, their postulated normal counterpart. Validation was performed by immunohistochemistry (IHC), whereas functional experiments were carried out ex vivo. For the first time at the molecular level, we definitely recognized the cellular derivation of BPDCN that proved to originate from the myeloid lineage and in particular, from resting pDCs. Furthermore, thanks to an integrated bioinformatic approach we discovered aberrant activation of the NF-kB pathway and suggested it as a novel therapeutic target. We tested the efficacy of anti-NF-kB-treatment on the BPDCN cell line CAL-1, and successfully demonstrated by GEP and IHC the molecular shutoff of the NF-kB pathway. In conclusion, we identified a molecular signature representative of the transcriptional abnormalities of BPDCN and developed a cellular model proposing a novel therapeutic approach in the setting of this otherwise incurable disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据